Activation of SUCNR1 has been reported in many cancer types and can activate several downstream pathways including Erk1/2 [236], prostaglandin E2 (PGE2) [233], p38 MAPK [237], Akt [233], and AMPK [227] with various effects. This evidence concerns the gene MAPK3 and cancer.